Helixmith Co., Ltd (KOSDAQ:084990)
South Korea
· Delayed Price · Currency is KRW 2,360.00
+30.00 (1.27%)
Apr 1, 2025, 3:30 PM KST
Helixmith Revenue
In the year 2024, Helixmith had annual revenue of 4.97B KRW with 18.38% growth. Helixmith had revenue of 1.63B in the quarter ending December 31, 2024, with 203.14% growth.
Revenue
4.97B
Revenue Growth
+18.38%
P/S Ratio
22.31
Revenue / Employee
69.08M
Employees
72
Market Cap
108.67B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4.97B | 772.35M | 18.38% |
| Dec 31, 2023 | 4.20B | 1.40B | 50.08% |
| Dec 31, 2022 | 2.80B | 483.36M | 20.87% |
| Dec 31, 2021 | 2.32B | -1.93B | -45.48% |
| Dec 31, 2020 | 4.25B | -206.22M | -4.63% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2013 | Pro | Pro | Pro |
| Dec 31, 2012 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4,547.32B |
| Celltrion | 3,557.30B |
| ALTEOGEN | 102.85B |
| Yuhan | 2,067.79B |
| SK Biopharmaceuticals | 547.60B |
| HLB Co., Ltd. | 51.92B |
| Sam Chun Dang Pharm. | 210.92B |
| PharmaResearch | 350.12B |